首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >In Silico Design for Adenosine Monophosphate-Activated Protein Kinase Agonist from Traditional Chinese Medicine for Treatment of Metabolic Syndromes
【24h】

In Silico Design for Adenosine Monophosphate-Activated Protein Kinase Agonist from Traditional Chinese Medicine for Treatment of Metabolic Syndromes

机译:用于治疗代谢综合征的中药腺苷单磷酸激活蛋白激酶激动剂的计算机设计

获取原文
获取原文并翻译 | 示例
           

摘要

Adenosine monophosphate-activated protein kinase (AMPK) acts as a master mediator of metabolic homeostasis. It is considered as a significant millstone to treat metabolic syndromes including obesity, diabetes, and fatty liver. It can sense cellular energy or nutrient status by switching on the catabolic pathways. Investigation of AMPK has new findings recently. AMPK can inhibit cell growth by the way of autophagy. Thus AMPK has become a hot target for small molecular drug design of tumor inhibition. Activation of AMPK must undergo certain extent change of the structure. Through the methods of structure-based virtual screening and molecular dynamics simulation, we attempted to find out appropriate small compounds from the world's largest TCM Database@Taiwan that had the ability to activate the function of AMPK. Finally, we found that two TCM compounds, eugenyl_beta-D-glucopyranoside and 6-O-cinnamoyl-D-glucopyranose, had the qualification to be AMPK agonist.
机译:腺苷单磷酸激活的蛋白激酶(AMPK)充当代谢稳态的主要介体。它被认为是治疗包括肥胖症,糖尿病和脂肪肝在内的代谢综合症的重要磨石。它可以通过开启分解代谢途径来感知细胞的能量或营养状况。 AMPK的调查最近有新发现。 AMPK可通过自噬抑制细胞生长。因此,AMPK已经成为抑制肿瘤的小分子药物设计的热点。 AMPK的激活必须进行一定程度的结构改变。通过基于结构的虚拟筛选和分子动力学模拟的方法,我们试图从世界上最大的TCM Database @ Taiwan中找到合适的小化合物,这些化合物能够激活AMPK的功能。最后,我们发现两种中药化合物,分别为戊二烯基-β-D-吡喃葡萄糖苷和6-O-肉桂酰基-D-吡喃葡萄糖,具有AMPK激动剂的资格。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号